However, that conclusion is confounded by two phase III clinical trials of anastrozole that found no overall benefit from a 10 mg dose (versus 1 mg), indicating that an increased dosage may not be effective in overcoming obesity-induced resistance to aromatase inhibitors [16,17]. This evidence concerns the gene CYP19A1 and obesity due to melanocortin 4 receptor deficiency.